Outcome Capital shares their views, insights and data on key strategic trends and dynamics in the biopharma sector. This segment is poised for significant growth, scientific advancement and consolidation.
Market Insight: Mike Casasanta, PhD, Nick Frame, PhD and Oded Ben-Joseph, PhD
Outcome Capital shares their views, insights and data on key strategic trends and dynamics in the biopharma sector. This segment is poised for significant growth, scientific advancement and consolidation.
The New Orleans biotech is currently raising a tiny $8 million Series A to develop its non-opioid painkiller. It keeps costs low by paying employees cash on an hourly basis—but no salaries.
Read MoreOutcome Capital Life Science Market Pulse March 2025 Click to view our LifeSciences Pulse Newsletter
DownloadWould you like to learn more about working with Outcome Capital or discuss your specific needs?